Loading company…
Wuhan Healthgen develops plant-made pharmaceuticals using a rice endosperm cell expression platform.
Wuhan Healthgen uses its OryzHiExp rice endosperm cell platform to develop plant-made pharmaceuticals, including recombinant human serum albumin and other proteins. It also provides custom protein and peptide expression services. Founded in 2006 and based in Wuhan, the company raised approximately CNY 2.60 billion in an IPO in October 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Wuhan Healthgen Biotechnology Corp.? This is my company